Danaher(DHR)
Focus: Danaher is a diversified conglomerate with a major diagnostics business segment, operating at massive scale with 50,000+ employees and $23.9B in FY2025 revenue. As a public company (NYSE: DHR), it leverages the Danaher Business System to drive operational excellence across diagnostics, life sciences, and environmental solutions.
Profile data last refreshed 23h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Employees
50000+
Open Jobs
1322+494 this month
Hot — 1848 jobs added in 30d
Net +494 (1848 new, 1354 removed). Aggressive expansion phase.
Should You Work at Danaher?
AI assessmentDanaher offers financial stability and scale within diagnostics, but declining revenues and thin clinical pipelines make it a career choice for operational excellence and commercial growth rather than drug discovery or novel therapeutic development.
Why Work Here
- Access to world-class diagnostics infrastructure and 50,000+ employee network — rare organizational scale for professional development
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$23.9B
Pipeline & Clinical Trials
N/A
Clinical Trials (1)
NCT06551116QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
N/AHelp build intelligence for Danaher
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.